LSD microdoses boost reward processing in depressed brains — while firefighters face barriers to ketamine PTSD treatment
This week brought fascinating insights into how psychedelics affect the brain differently based on mental health status, plus sobering realities about treatment access for those who need it most.
🧠 LSD Microdoses Rewire Reward Processing—But Only in Depressed Brains
20 participants with mild-to-moderate depression got tiny doses of LSD (26 μg) and showed enhanced brain responses to losing money—suggesting their brains were processing emotional rewards more intensely
The effect was specific: LSD only changed reward-related brain activity in depressed participants, not in the 19 healthy controls
Those who had stronger brain responses to LSD also reported better moods immediately after treatment and lower depression scores 48 hours later
Why it matters: This suggests LSD microdoses may work by helping depressed brains pay more attention to emotional experiences, potentially explaining why some people report mood benefits from tiny psychedelic doses.
Key Findings
🚒 Firefighters Hit Roadblocks Getting Ketamine for PTSD
6 firefighters enrolled in a ketamine-assisted therapy program but couldn't start treatment due to barriers like stigma, financial costs, and complex logistics
Firefighters face PTSD rates of 7.3% compared to just 1.3-3.5% in the general population, yet struggle with both workplace stigma around mental health and skepticism about ketamine treatment
Self-advocacy emerged as crucial—firefighters had to navigate insurance, find providers, and manage scheduling around demanding work shifts
🔬 Ketamine Withdrawal Scrambles Memory in Young Female Rats
Adolescent female rats given recreational doses of ketamine (10 mg/kg for 3 days) showed impaired episodic, social, and working memory 24 hours after their last dose
Brain analysis revealed significantly reduced serotonin and norepinephrine levels in the hippocampus and prefrontal cortex during withdrawal
The study mimicked weekend party use patterns, suggesting even short-term recreational ketamine use may disrupt multiple memory systems
📊 Nearly Half of Synthetic Drug Seizures Turn Deadly
A review of 42 cases found that seizures from synthetic cathinones and phenethylamines (designer stimulants) resulted in death in nearly 50% of cases
Beyond the expected serotonin toxicity, many fatal cases involved preventable complications like brain hemorrhage, cerebral swelling, low blood sugar, and dangerously low sodium levels
Most victims were previously healthy young adults, suggesting these complications might be treatable if recognized early
⚡ Lithium Tops List for Preventing Depression Relapse After Electroshock
A review of 28 studies covering 11,119 patients found lithium (alone or with antidepressants) most consistently prevented depression from returning after successful electroconvulsive therapy
Continuation ECT combined with medication also showed strong evidence for preventing relapse across multiple randomized trials
Only 2 studies examined psychotherapy for relapse prevention, revealing a major research gap despite about 50% of patients relapsing within a year
🎯 Ketamine-Induced Brain States Mirror PTSD Patterns
30 healthy volunteers given ketamine showed brain network changes resembling those seen in 78 PTSD patients—specifically increased default mode network activity and decreased somatomotor network activity
PTSD patients who improved after treatment showed reduced default mode network dominance, correlating with fewer dissociative symptoms
The similarity suggests dissociation may involve specific, measurable brain network patterns regardless of whether it's drug-induced or trauma-related
🧪 Portuguese Hospital Tests Ketamine-Psychotherapy Combo
All 9 patients with treatment-resistant depression improved after 8 weeks of ketamine infusions plus psychotherapy, with depression scores shifting from severe to moderate levels
44% of patients showed strong responses (≥50% reduction in depression scores), and over half of those with suicidal thoughts saw those symptoms disappear
Only 29% of patients experienced mood deterioration within 3 months after treatment ended, suggesting relatively durable benefits
Implications
This week's research reveals how psychedelics and related treatments work differently depending on individual brain states and mental health conditions. While the science shows promise—from LSD's selective effects in depression to ketamine's potential for severe cases—real-world implementation faces significant barriers around access, safety monitoring, and long-term support systems.
Studies in this issue
Primary sources used for this newsletter.
- Brain reward system activity after low doses of LSD in people with depressed moodmain storyJournal of psychopharmacology (Oxford, England)2026-01-13PMID 41529826
- Triggers of Deadly Seizures Caused by New Synthetic Stimulant Drugskey findingNeurotoxicology2026-01-16PMID 41544778
- Relapse-prevention methods after successful electroconvulsive therapy for major depression: a systematic reviewkey findingBJPsych open2026-01-14PMID 41530963
- Short-term ketamine withdrawal affects memory and mood-related brain chemicals in adolescent female ratskey findingBehavioural brain research2026-01-18PMID 41548718
- Ketamine and Therapy for Hard-to-Treat Depression in a Public European Hospitalkey findingBrain and behavior2026-01-13PMID 41527475
- Challenges Firefighters Face Getting Ketamine Therapy for PTSDkey findingJournal of Occupational and Environmental Medicine2026-01-16PMID 41540564
- Brain activity patterns during ketamine-induced dissociation are similar to those in posttraumatic stress disorderkey findingBiological psychiatry global open science2026-01-19PMID 41552776
Continue reading
All Psychedelic Science issuesGet the next Psychedelic Science issue
Seven papers, once a week. Free.